Search: onr:"swepub:oai:DiVA.org:liu-14489" > Plasma S/R ratio of...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 02803naa a2200301 4500 | |
001 | oai:DiVA.org:liu-14489 | |
003 | SwePub | |
008 | 070521s2007 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-144892 URI |
024 | 7 | a https://doi.org/10.1097/MBC.0b013e3280444bfd2 DOI |
040 | a (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Osman, Abdimajidu Östergötlands Läns Landsting,Linköpings universitet,Klinisk kemi,Hälsouniversitetet4 aut0 (Swepub:liu)majos21 |
245 | 1 0 | a Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype |
264 | 1 | c 2007 |
338 | a print2 rdacarrier | |
520 | a We recently reported that the low-dose VKORC1*2 haplotype is an important genetic determinant for warfarin dose requirement and is associated with difficulties to attain stable therapeutic prothrombin time-International Normalized Ratio in patients undergoing anticoagulation therapy. The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different warfarin S/R ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors. Samples from patients previously haplotyped for VKORC1 and measured for plasma warfarin concentration were genotyped for the CYP2C9 variants CYP2C9*2 and CYP2C9*3. Nonparametric statistical analysis was performed to elucidate whether there was any significant difference in the warfarin S/R ratio between the two patient groups. Our result shows that there is a significant difference (P < 0.01) in warfarin S/R ratios between VKORC1*2 and VKORC1*3 or VKORC1*4 patients. This difference did not originate from CYP2C9 variants CYP2C9*2 and CYP2C9*3. We speculate that VKORC1 haplotypes possibly are linked to some unidentified factors involved in the metabolic clearance of warfarin enantiomers. Dose-dependent variations in (S)-warfarin and (R)-warfarin clearance in these patients can also be a probable explanation for the difference in warfarin S/R ratios. | |
653 | a MEDICINE | |
653 | a MEDICIN | |
700 | 1 | a Enström, Camillau Linköpings universitet,Institutionen för biomedicin och kirurgi,Hälsouniversitetet4 aut0 (Swepub:liu)camen30 |
700 | 1 | a Lindahl, Tomasu Östergötlands Läns Landsting,Linköpings universitet,Klinisk kemi,Hälsouniversitetet4 aut0 (Swepub:liu)tomli13 |
710 | 2 | a Linköpings universitetb Klinisk kemi4 org |
773 | 0 | t Blood Coagulation and Fibrinolysisg 18:3, s. 293-296q 18:3<293-296x 0957-5235x 1473-5733 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-14489 |
856 | 4 8 | u https://doi.org/10.1097/MBC.0b013e3280444bfd |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.